In May,Tongee was selected as one of the first batch of specialized, refined, characteristic, and novel new small and medium-sized enterprises (SMEs) in Zhejiang Province in 2023.

In June,Tongee received investment from "Shenzhen Topping Venture Capital Fund and Wuxi Guolian Xinchuang”.

In September, Tongee obtained its first Class II registration certificate for medical device of People’s Republic of China.

In October, Tongee obtained the Production Enterpriser Licence of Medlical Instrument.

In November,Tongee reached strategic cooperation with the Metabolic Disorder Industrial Campus, initiated by Academician Guang Ning.

In January, the registered clinical trial of "Gastric Bypass Stent System" was initiated.

In March, the Gastric Bypass Stent was successfully implanted in the first subject of the registered clinical trial.

In May, Tongee received investments from "Baidu Ventures" and "Everest Venture Capital".

In June,Tongee's brand new R&D center that integrates versatile functions including scientific research, trial manufacturing, manufacturing, inspection and other functions was officially established in Binjiang District, Hangzhou.

In November,Tongee Shanghai Branch "Shuchuang Tech" was officially established, kicking off its comprehensive layout in the East China market.

In December,Tongee donated thousands of Covid-19 prevention items, contributing to Covid-19 prevention and control in Zhejiang Province.

In August, the "Gastric Bypass Stent System" passed the "Special Approval Procedure on China's Innovative Medical Devices" of the NMPA Center for Medical Device Evaluation.

In October, Tongee received an investment from "Ningbo JunJing Management Consulting ".

In May, Tongee received an investment from "Shanghai Fang and Investment Center".

In June, the "Gastric Bypass Stent System" submitted the bench test report.

In May, Tongee received investments from "Shenzhen Dingxin Capital Management Co., Ltd." and "Virtus Inspire Ventures".

In August, a sample of the "first Gastric Balloon" was successfully produced.

In September, as a new technology for the diagnosis and treatment of endocrine and metabolic diseases, the clinical research on Gastric Bypass Stent in the treatment of obese non-alcoholic fatty liver diseases was approved, which was a "provincial key R&D project" jointly applied by Tongee, Zhejiang University and Zhejiang Chinese Medical University.

In December, the scientific and clinical researches on the "Gastric Bypass Stent System" were initiated.

In March, a sample of the "Gastric Bypass Stent System" was successfully produced.

In April, a 100,000-grade purification workshop of GMP standard with an area of 600 square meters was built.

In August, Tongee was formally founded and R&D was initiated.

In October, Tongee was shortlisted in the "5050 Plan" which was officially launched by Binjiang government and received a governmental financial support of 5 million yuan.

In December, Tongee received investment from "Hangzhou Proxima Innovation Investment" and "Virtus Inspire Ventures".